Lexus Granito manufactures and markets vitrified ceramic floor and wall tiles for residential and commercial construction in India and international markets.
The company operates in a highly fragmented, commodity-driven industry with no evidence of brand premium or cost advantage, as evidenced by persistent negative net margins and declining revenues. The lack of pricing power is confirmed by the inability to pass on costs, leading to massive cash losses and a deteriorating return on capital.
Management has overseen a period of severe value destruction, with average ROE at -43.7% and a debt-to-equity ratio ballooning to over 3.0. Capital has been tied up in non-productive inventory and receivables while the company defaulted on debenture settlements.
The company's collapse was precipitated by a liquidity trap where stagnant inventory and uncollectible receivables failed to cover mounting debt obligations. Following the default on debenture settlements, the CGST tax liabilities crystallized into immediate cash outflows that the business could not sustain. As the NFRA-sanctioned audit failures came to light, credit lines were severed, and the company was forced into a fire-sale liquidation of its commodity assets to satisfy statutory dues and secured lenders, leaving equity holders with nothing.
RichFakir rates Lexus Granito (India) Ltd's business quality as poor — 2/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Lexus Granito (India) Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Lexus Granito (India) Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Lexus Granito (India) Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →